Gastric Cancer Drugs Market - Global Industry Analysis, Trends and Forecast, 2013 - 2019

Gastric cancer refers to the cancer arising from lining of stomach. It may lead to uncontrolled growth of malignant cells that originate in stomach tissue and forms a tumor in any part of the stomach. Mainly there are five types of gastric cancer namely adenocarcinoma, squamous cell cancer, lymphoma, gastrointestinal stromal tumors, neuroendocrine tumors. 

From all these types, adenocarcinoma types of cancer originates from the innermost lining of stomach and accounts for more than 90% of all gastric tumors. Dysphagia, frequent burping, heartburn, stomachache are some of the early stomach cancer symptoms. The drugs of gastric cancers works on extracellular and intracellular domain of HER2 receptor of stomach and continuously suppress the tumor proliferation that lead to cell stasis and death. 

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1853

According to World Health Organization, approximately 800,000 cancer related deaths are caused by gastric cancer every year and American Cancer Society estimated that in 2013 approximately 21,600 cases of gastric cancer will be diagnosed. This increasing incidences of gastric cancer drives the market of gastric cancer drugs. In addition, introduction of new therapies like Taxotere, Xeloda and Herceptin are also expected to propel the demand for gastric cancer drugs. However, less number of commercially available drugs for the treatment of gastric cancer may hinder the market growth.

The global Gastric Cancer Drug market is categorized based on the following:

By Class of Drugs

• Doxorubicin Hydrochloride
• Fluorouracil
• Trastuzumab
• Mitomycin C
• Docetaxel
• Imatinib
• Sunitinib

Geographically, China and Japan dominate the global gastric cancer drug market due to large patient base and rise in treatment seeking population in these regions. Also, with the rise in geriatric population the number of people diagnosed with gastric cancer also increases which ultimately impacts the growth of gastric cancer drugs in these markets. 

The market of gastric cancer drug in North America and Europeholds a strong growth as the key players are domiciled in these regions. With the rise in uptake of gastric cancer drugs namely is Herceptin, Erbitux and Afitnitor also accentuates the growth of these drugs in the North American and European market.However, the total number of newly diagnosed patients are five times greater in China and Japan than the United States, making Japanese and Chinese market commercially attractive for developers.

Some of the key players contributing to the global gastric cancer drug market comprises F Hoffmann-La Roche, Genentech, Novartis AG, Merck KGaA, Sanofi-Aventis, Otsuka Pharmaceutical and Eli Lilly and Company.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.